journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/28316091/2b-or-not-2b-a-prothrombotic-tendency-masquerading-as-a-bleeding-disorder
#1
Yvonne Brennan, Jennifer Curnow, Emmanuel J Favaloro
No abstract text is available yet for this article.
March 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28316085/haploidentical-bone-marrow-transplantation-in-patients-with-advanced-myelodysplastic-syndrome
#2
LETTER
Riccardo Varaldo, Anna Maria Raiola, Carmen Di Grazia, Sara Aquino, Germana Beltrami, Stefania Bregante, Fabio Cruciani, Alida Dominietto, Anna Ghiso, Livia Giannoni, Francesca Gualandi, Adalberto Ibatici, Teresa Lamparelli, Carlo Marani, Maria Teresa Van Lint, Valeria Santini, Andrea Bacigalupo, Emanuele Angelucci
No abstract text is available yet for this article.
March 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28314085/targeted-next-generation-sequencing-and-identification-of-risk-factors-in-world-health-organization-defined-atypical-chronic-myeloid-leukemia
#3
Mrinal M Patnaik, Daniela Barraco, Terra L Lasho, Christy M Finke, Kaaren Reichard, Katherine P Hoversten, Rhett P Ketterling, Naseema Gangat, Ayalew Tefferi
Atypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly-annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8% and PTPN11 4%...
March 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28314084/treatment-patterns-and-outcome-following-initial-relapse-or-refractory-disease-in-patients-with-systemic-light-chain-amyloidosis
#4
Nidhi Tandon, Surbhi Sidana, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Amie L Fonder, Miriam A Hobbs, Suzanne R Hayman, Wilson I Gonsalves, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, John A Lust, Stephen J Russell, Steven R Zeldenrust, S Vincent Rajkumar, Shaji K Kumar
We analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of type of therapy employed.A total of 1327 patients with AL seen at Mayo Clinic within 90 days of diagnosis, between 2006 and 2015, were reviewed. The study included 366 patients experiencing a documented hematological or organ relapse or refractory disease requiring start of second line therapy. Overall survival (OS) and time to next treatment (TTNT) were calculated from start of second line treatment...
March 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295559/correcting-a-25-year-old-error-preanalytical-conditions-affect-determination-of-von-willebrand-factor-variability-as-a-function-of-menstrual-cycle
#5
LETTER
Margareta Blombäck
No abstract text is available yet for this article.
March 15, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295518/telomere-attrition-in-sickle-cell-anemia
#6
LETTER
Armand Mekontso Dessap, Jérôme Cecchini, Vicky Chaar, Elisabeth Marcos, Anoosha Habibi, Pablo Bartolucci, Bijan Ghaleh, Frederic Galacteros, Serge Adnot
No abstract text is available yet for this article.
March 15, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295472/outcomes-of-adults-with-relapsed-or-refractory-burkitt-and-high-grade-b-cell-leukemia-lymphoma
#7
LETTER
Nicholas J Short, Hagop M Kantarjian, Heidi Ko, Joseph D Khoury, Farhad Ravandi, Deborah A Thomas, Guillermo Garcia-Manero, Maria Khouri, Jorge E Cortes, William G Wierda, Srdan Verstovsek, Zeev Estrov, Alessandra Ferrajoli, Philip A Thompson, Sherry Pierce, Susan M O'Brien, Elias Jabbour
No abstract text is available yet for this article.
March 15, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295532/beyond-the-transition-of-adolescents-and-young-adults-with-sickle-cell-disease-to-adult-care-role-of-geography
#8
LETTER
Nina Anderson, James R Eckman, Samir K Ballas
No abstract text is available yet for this article.
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295527/factors-predicting-survival-in-chronic-lymphocytic-leukemia-patients-developing-richter-syndrome-transformation-into-hodgkin-lymphoma
#9
Francesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, Luca Laurenti, Giovanni Del Poeta, Gianluigi Reda, Marina Motta, Alessandro Gozzetti, Roberta Murru, Maria Denise Caputo, Melissa Campanelli, Anna Maria Frustaci, Idanna Innocenti, Sara Raponi, Anna Guarini, Fortunato Morabito, Robin Foà, Massimo Gentile
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41-80) and 70 years (range 46-82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0-258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) ≥4 in 50%, extranodal involvement in 39%, B symptoms in 70%...
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295510/ibrutinib-in-very-elderly-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-a-real-world-experience-of-71-patients-treated-in-france-a-study-from-the-french-innovative-leukemia-organization-filo-group
#10
LETTER
Anne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, Marie-Sarah Dilhuydy, Olivier Tournilhac, Luc-Matthieu Fornecker, Jehan Dupuis, Florence Cymbalista, Sophie De Guibert, Alain Delmer, Jean-Pierre Vilque, David Ghez, Veronique Leblond, Fabien Subtil, Pierre Feugier, Loic Ysebaert
No abstract text is available yet for this article.
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295502/assessment-of-renal-response-with-urinary-exosomes-in-patients-with-al-amyloidosis-a-proof-of-concept
#11
Marina Ramirez-Alvarado, David R Barnidge, David L Murray, Angela Dispenzieri, Marta Marin-Argany, Christopher J Dick, Shawna A Cooper, Samih H Nasr, Christopher J Ward, Surendra Dasari, Víctor H Jiménez-Zepeda, Nelson Leung
Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B-cell proliferation secondary to deposition of amyloid fibrils in various organs. Urinary exosomes (UEX) are the smallest of the microvesicles excreted in the urine. Previously, we found UEX of patients with AL amyloidosis contained immunoglobulin light chain (LC) oligomers that patients with multiple myeloma did not have. To further explore the role of the LC oligomers, UEX was isolated from an AL amyloidosis patient with progressive renal disease despite achieving a complete response...
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28295477/erythrocytes-from-hereditary-xerocytosis-patients-heterozygous-for-kcnn4-v282m-exhibit-increased-spontaneous-gardos-channel-like-activity-inhibited-by-senicapoc
#12
LETTER
Alicia Rivera, David H Vandorpe, Boris E Shmukler, Denis R Gallagher, Christopher C Fikry, Frans A Kuypers, Carlo Brugnara, L Michael Snyder, Seth L Alper
No abstract text is available yet for this article.
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28263406/recombinant-erythropoietin-vs-blood-transfusion-care-in-infants-with-hereditary-spherocytosis-a-retrospective-cohort-study-of-a-i-e-o-p-patients-associazione-italiana-emato-oncologia-pediatrica
#13
LETTER
Piero Farruggia, Giuseppe Puccio, Ugo Ramenghi, Raffaella Colombatti, Paola Corti, Angela Trizzino, Angelica Barone, Gianluca Boscarol, Fabrizia Ferraro, Paolo Grotto, Laura Lo Valvo, Laura Luti, Sofia Maria Rosaria Matarese, Clara Mosa, Maria Caterina Putti, Laura Rubert, Giovan Battista Ruffo, Laura Sainati, Immacolata Tartaglione, Giovanna Russo, Silverio Perrotta
No abstract text is available yet for this article.
March 6, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28263404/the-association-between-race-and-venous-thromboembolism-risk-after-initiation-of-chemotherapy-an-analysis-of-the-save-onco-trial-control-arm
#14
LETTER
Yu-Wei Chen, Alok Khorana
No abstract text is available yet for this article.
March 6, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28263402/incidence-clinical-findings-and-survival-of-hepatosplenic-t-cell-lymphoma-in-the-united-states
#15
LETTER
Urshila Durani, Ronald S Go
No abstract text is available yet for this article.
March 6, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28253536/myeloid-neoplasms-with-concurrent-bcr-abl1-and-cbfb-rearrangements-a-series-of-10-cases-of-a-clinically-aggressive-neoplasm
#16
Alireza Salem, Sanam Loghavi, Guilin Tang, Yang O Huh, Elias J Jabbour, Hagop Kantarjian, Wei Wang, Shimin Hu, Rajyalakshmi Luthra, L Jeffrey Medeiros, Joseph D Khoury
Chronic myeloid leukemia (CML) is defined by the presence of t(9;22)(q34;q11.2)/BCR-ABL1. Additional chromosomal abnormalities confer an adverse prognosis and are particularly common in the blast phase of CML (CML-BP). CBFB rearrangement, particularly CBFB-MYH11 fusion resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22), is an acute myeloid leukemia (AML)-defining alteration that is associated with a favorable outcome. The co-occurrence of BCR-ABL1 and CBFB rearrangement is extremely rare, and the significance of this finding remains unclear...
March 2, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28249352/utility-of-factor-viii-and-factor-viii-to-von-willebrand-factor-ratio-in-identifying-277-unselected-carriers-of-hemophilia-a
#17
LETTER
Veerle Labarque, Vanitha Perinparajah, Vanessa Bouskill, Ann Marie Stain, Cindy Wakefield, Cecilia Manuel, Victor S Blanchette, Paula D James, David Lillicrap, Manuel D Carcao
No abstract text is available yet for this article.
March 1, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28247997/bcl2-mutations-do-not-confer-adverse-prognosis-in-follicular-lymphoma-patients-treated-with-rituximab
#18
Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, Luc Xerri, Wayne J Fairbrother, Kiran Mukhyala, Chris Bolen, Elizabeth Punnoose, Laurie Tonon, Catherine Chassagne-Clément, Pierre Feugier, Alain Viari, Fabrice Jardin, Gilles Salles, Pierre Sujobert
BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 FL patients treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (Activation-induced cytidine deaminase) in the context of the t(14;18) translocation...
March 1, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28247462/a-centrocyte-blood-count-of-a-quarter-million
#19
Matthew Behrens, Rajasree P Chowdry, Saliba Saba, Nakhle S Saba
No abstract text is available yet for this article.
March 1, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28247421/dynamic-assessment-of-rbc-transfusion-dependency-improves-the-prognostic-value-of-the-revised-ipss-in-mds-patients
#20
Devendra K Hiwase, Deepak Singhal, Corinna Strupp, Rakchha Chhetri, Monika M Kutyna, L Amilia Wee, Peter B Harrison, Shriram V Nath, Nicholas Wickham, Chi-Hung Hui, James X Gray, Peter Bardy, David M Ross, Ian D Lewis, John Reynolds, L Bik To, Ulrich Germing
RBC-transfusion dependency (RBC-TD) is an independent prognostic factor for poor overall survival (OS) in the WHO classification-based prognostic scoring system (WPSS) for MDS patients. However, WPSS did not include cytopenia, whereas revised International Prognostic Scoring System (IPSS-R) did not include RBC-TD. Thus, neither of these prognostic scoring systems incorporates both cytopenia and RBC-TD. We aimed to test whether RBC-TD adds prognostic value to the IPSS-R. We analyzed MDS patients not treated with disease-modifying therapy, and enrolled in SA-MDS Registry (derivation cohort; n=295) and Dusseldorf registry (Germany; validation cohort; n=113) using time-dependent Cox proportional regression and serial landmark analyses...
March 1, 2017: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"